Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brepocitinib (Primary)
Indications Dermatomyositis
Focus Registrational; Therapeutic Use
Acronyms VALOR
Sponsors Priovant Therapeutics

Most Recent Events

29 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jul 2025.
27 Nov 2024 Planned End Date changed from 1 Dec 2024 to 1 Jul 2026.
29 Jul 2024 According to a Roivant Sciences media release, Data are expected in the second half of 2025 with potential dermatomyositis NDA submission to follow.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com